Literature DB >> 17414583

Update of diuretics in the treatment of hypertension.

María Cristina Armas Padilla1, María José Armas-Hernández, Rafael Hernández Hernández, Zafar H Israili, Manuel Valasco.   

Abstract

Diuretics, which are primarily used to modify the volume and the composition of body fluids, are widely used to treat hypertension. The diuretics include a) the thiazides and thiazide-like agents, which are the most common drugs used to treat high blood pressure (these drugs inhibit sodium reabsorption in the early distal convoluted tubule); b) loop diuretics, such as furosemide, block chloride and sodium reabsorption by inhibition of the Na/K/2Cl cotransport system in the thick ascending limb of the loop of Henle; and c) potassium-sparing (retaining) diuretics, including aldosterone receptor blockers (such as spironolactone and eplerenone) and epithelial sodium channel blockers (such as amiloride and triamterene, which interfere with the reabsorption of sodium and excretion of potassium and hydrogen that takes place in the late distal tubule, the connecting tubule, and the cortical collecting duct). Hydrochlorothiazide 12.5 mg once daily or equivalent low dosages of other similar agents reduce blood pressure in approximately one-half to two-thirds of patients who are responsive to this class of drugs; higher doses add little to the effect on blood pressure and also increase side effects. Some combinations of very small doses of thiazide diuretics - for example, 6.25 mg hydrochlorothiazide or 0.625 mg indapamide, with a low dose of an antihypertensive drug of a different class - have average antihypertensive efficacy when used once daily. Furosemide is used in patients with renal failure or severe heart failure and is best given by continuous intravenous infusion. The potassium-sparing diuretics are generally used in combination with thiazide diuretics to treat hypertension. Side effects occur at about the same frequency and severity with equipotent doses of all diuretics. The incidence of side effects is dose-dependent and also increases as a function of the duration of the renal excretory and antihypertensive actions. However, longer-acting diuretics provide better 24-hour control of blood pressure and increase compliance and adherence to the treatment regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414583     DOI: 10.1097/01.pap.0000249938.05382.d0

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  12 in total

Review 1.  Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China.

Authors:  Yiqun Wu; Yonghua Hu; Xun Tang; Liu He; Tao Ren; Qiushan Tao; Xueying Qin; Ningling Sun; Hongyi Wang; Weihua Cao; Tao Wu; Siyan Zhan; Jin Wang; Weihua Chen; Liming Li
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

3.  Use of combination antihypertensive therapy initiation in older Americans without prevalent cardiovascular disease.

Authors:  Xiaojuan Li; Wendy Camelo Castillo; Til Stürmer; Virginia Pate; Christine L Gray; Ross J Simpson; Soko Setoguchi; Laura C Hanson; Michele Jonsson Funk
Journal:  J Am Geriatr Soc       Date:  2014-08-12       Impact factor: 5.562

4.  The small molecule phenamil is a modulator of adipocyte differentiation and PPARgamma expression.

Authors:  Kye Won Park; Hironori Waki; Sung-Pil Choi; Ki-Moon Park; Peter Tontonoz
Journal:  J Lipid Res       Date:  2010-06-02       Impact factor: 5.922

5.  The small molecule phenamil induces osteoblast differentiation and mineralization.

Authors:  Kye Won Park; Hironori Waki; Woo-Kyun Kim; Brandon S J Davies; Stephen G Young; Farhad Parhami; Peter Tontonoz
Journal:  Mol Cell Biol       Date:  2009-05-11       Impact factor: 4.272

6.  Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension.

Authors:  Steen Neldam; Colin Edwards
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-08       Impact factor: 3.738

7.  Clinical approach in treatment of resistant hypertension.

Authors:  Jennifer Frank; David Sommerfeld
Journal:  Integr Blood Press Control       Date:  2009-07-30

Review 8.  The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.

Authors:  Hakuo Takahashi; Masamichi Yoshika; Yutaka Komiyama; Masato Nishimura
Journal:  Hypertens Res       Date:  2011-08-04       Impact factor: 3.872

9.  Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients.

Authors:  Hall Schartum-Hansen; Per M Ueland; Eva R Pedersen; Klaus Meyer; Marta Ebbing; Øyvind Bleie; Gard F T Svingen; Reinhard Seifert; Bjørn E Vikse; Ottar Nygård
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

Review 10.  Which thiazide to choose as add-on therapy for hypertension?

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.